Metabolic factors and the risk of colorectal cancer by <i>KRAS</i> and <i>BRAF</i> mutation status

Myte, Robin; Gylling, Björn; Häggström, Jenny; Häggström, Christel; Zingmark, Carl; Burström, Anna Löfgren; Palmqvist, Richard; Guelpen, Bethany Van

doi:10.1002/ijc.32104

Cited by 16 publications

(22 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 1,003 CRC patients with BRAF test, 23 patients with a positive BRAF mutation was found with a mutation rate of 2.29% -much lower than that in the published data of 8-10% (Bahrami et al, 2018;Myte et al, 2019). This result indicated that BRAF mutation rate was specifically low in eastern China patients.…”

Section: Braf Mutation Was Specifically Low In Eastern China Crc Patimentioning

confidence: 62%

See 1 more Smart Citation

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases

et al. 2020

View full text Add to dashboard Cite

Colorectal cancer (CRC) has become a major health concern in China due to its increasing incidence and mortality. This study aimed to clarify the relationship between tumor locations and the clinicopathological molecular marker features in eastern China CRC patients. We continuously collected data on 2,356 CRC patients who underwent surgical resection from January 2017 to April 2019. Right-sided colorectal cancer (RCC), was located from the cecum to the transverse colon and left-side colorectal cancer (LCRC) was located from the splenic flexure to the rectum. The clinicopathological indices (including age, sex, pTNM stage, mucinous production, and distant metastasis) and frequency of molecular markers such as KRAS, NRAS, BRAF, and microsatellite instability (MSI) were statistically analyzed between the RCC and LCRC groups. The associations between clinicopathological characters and molecular markers were also investigated. LCRC and RCC proportions in eastern China CRC patients were 81.75% and 18.25%, respectively. RCC (vs. LCRC) was more frequently observed with higher frequencies of MSI-high (MSI-H) and BRAF mutations in female and younger patients, and was closely associated with metastasis, poor differentiation, and mucinous tumors. Tumor location also showed significant differences in bowel wall infiltration degree and pTNM stage. Mutation rates of KRAS, NRAS, MSI, and BRAF were 40.15%, 3.85%, 6.31%, and 2.30%, respectively. Patients with a KRAS mutation tended to be female, had mucinous, perineural invasive, and polypoid tumor. Those with NRAS mutation tended to develop well-differentiated ulcerative tumors. The BRAF mutation was more relevant with lymph node involvement, deeper infiltration of the bowel wall, mucinous, poorly-differentiated tumor with thrombus, and perineural invasion. Furthermore, MSI-H was more commonly found in younger patients with deeper bowel wall infiltration and a poorly-differentiated polypoid tumor, whereas MSS patients tended to develop lymph node involvement, and a mucinous and perineural invasive tumor. In our study, we found that LCRC and RCC showed different features on the clinicopathological and molecular markers in eastern China CRC patients. Since our data differ from those of Western countries and other

show abstract

Section: Braf Mutation Was Specifically Low In Eastern China Crc Patimentioning

confidence: 62%

“…The most frequent mutation point of BRAF is V600E. The incidence of the BRAF V600E mutation is estimated to be about 8-10% in CRC patients (Bahrami et al, 2018;Myte et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Associations between environmental factors and KRAS status have not been extensively investigated. Only a few studies have reported inconsistent findings regarding associations between BMI/metabolic parameters and KRAS status [14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location

Tabuso

Christian

Kimani

et al. 2020

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is characterized by complex interplay between macroenvironmental factors and tumour microenvironment, leading to variable outcomes in CRC patients. To date, there is still a need to identify macroenvironment/microenvironment factors that could define subgroup of patients that would benefit from specific anti-cancer treatment in order to improve patient selection for individualized targeted-based therapy. Aim of this study was to evaluate associations between metabolic parameters and KRAS status in metastatic CRC (mCRC) according to a new tumour site classification. Retrospective data were extracted from a total of 201 patients diagnosed with mCRC between 2012 and 2017 extracted from an established CRC database at our tertiary institute. Clinical-pathological data, including age, gender, BMI, hypertension, diabetes, pre-CRC diagnosis serum lipid levels and KRAS status were recorded. Categorical characteristics were compared using chi-squared test. Continuous characteristics were compared using Mann-Whitney U test. Log rank test was used to compare hazards for survival. In all comparisons, a two-sided P value <0.05 was considered statistically significant. Out of 201 patients, 170 patients with complete serum lipid profile were included in the analysis. In recto-sigmoid cancers there was a statistically significant association between high cholesterol:high-density lipoprotein (chol:HDL) ratio and KRAS mutation (OR 2.69, 95% CI 1.1-6.4, p = 0,02). In non recto-sigmoid cancers, high cholesterol was associated with KRAS WT (OR 0.39, CI 0.15-0.97, p = 0.04). In 22 patients with KRAS mutated recto-sigmoid cancer stage IV at diagnosis normal chol:HDL ratio was associated with a trend to better survival (p = 0.06). High chol:HDL ratio was significantly associated with KRAS mutated metastatic recto-sigmoid cancers. A subgroup of mCRC patients with KRAS mutated recto-sigmoid cancer may benefit from optimal lipid lowering treatment.

show abstract

“…CRC is heterogeneous cancer that is caused by multiple risk factors (12,13). Tumor heterogeneity as the greatest challenges must be considerable (14).…”

Section: Introductionmentioning

confidence: 99%

Development of Information Road map for Personalized Colorectal Cancer Screening in Iran

Maserat

Mohammadzadeh

Zali

2020

Preprint

View full text Add to dashboard Cite

Background A data-driven colorectal cancer screening strategy based on personalized approach can improve health outcomes, facilitate early stratification of at-risk patients and reduce health care costs. This study aims to develop an information road map for personalized colorectal cancer screening in Iran. Methods This study is a Mix-Method Research (MMR) which consisted of three phases: phase I, development of a checklist with 275-items for assessing required data elements of personalized colorectal cancer screening; phase II, situational analysis of colorectal cancer screening dataset according to the checklist; phase III, development of national information road map for personalized colorectal cancer screening with in-depth interview and focus groups. Results Personalized datasets of colorectal cancer screening were defined in four dimensions, including clinical dataset (5 sub-dimensions, 162 items), genetic dataset (2 sub-dimensions, 67 items), demographic dataset (1 sub-dimension, 6 items) and a social determinant dataset (3 sub-dimensions, 40 items). The next step data elements of colorectal cancer screening based on personalized datasets were analyzed. Of the 275-items, only 96 items are recorded. Only 17.8% of clinical dataset of screening program were entered. The highest data elements of clinical dimension were related to pathological datasets (53.6%) in the present screening program. The lowest data elements of the clinical dimensions were related to the clinical history dataset (3.4%). 73% of pedigree data elements and 15.33% of social determinant datasets were entered. In the final step, a national information road map of personalized CRC screening with 6 layers (information leadership, personalized datasets, data integration, data architecture, data descriptor, and screening program layers) was developed. Conclusion Personalized screening based on integration dataset play a key role for the successful implementation of the screening program. Eliminating data deficiencies can improve the quality of documentation and may lead to improved screening performance. Therefore, standard datasets and indicators can help to identify information gaps and facilitate precise decision-making. Entering data was inadequate and poor in this study. Implementation of national road map can assist to improve the quality of data in personalized screening.

show abstract

Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status

Cited by 16 publications

References 53 publications

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases

KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location

Development of Information Road map for Personalized Colorectal Cancer Screening in Iran

Contact Info

Product

Resources

About